Table 5.
Characteristics of studies included in comparable meta-analysis reporting PSM rate
| First author | Selection balance | Criteria for Intra-RP | Criteria for Inter-RP | SSOS for Intra-RP | Percent of pT2 cancer, % (Intra-RP vs Inter-RP) | PSM rate, % (Intra-RP vs Inter-RP) | ||
|---|---|---|---|---|---|---|---|---|
| pT2 | pT3 | all-stage | ||||||
| VIP 2005 | N | cT1c and PSA ≤ 10 and Gleason score ≤ 6 | cT2a/b or PSA > 10 ≤ 20 or Gleason score = 7 | 11 | 2.2: 3.3 | |||
| Zheng 2013 | N | cT1/2a and PSA ≤ 10 and Gleason score ≤ 3 + 4 and positive cores≤3/12 | cT2b/c or positive cores > 3/12 and PSA ≤ 10 and Gleason score ≤ 3 + 4 | 12 | 12.3: 16.2 | |||
| Khoder 2014 | N | cT1/2 and PSA ≤ 10 and Gleason score ≤ 6 | cT1/2 and PSA ≤ 15 and Gleason score ≤ 7 | 8 | 92.3: 81.9 | 8.8: 18.1 | 72.2: 51.5 | 13.7: 24.2 |
| Potdevin 2009 | Y | cT1/2a and PSA ≤ 10 and Gleason score ≤ 7 | 8 | 75.7: 88.3 | 7.5: 5.9 | 41.2: 22.2 | 15.7: 7.8 | |
| Neil 2009 | Y | cT1/2 and PSA ≤ 10 and absence of primary Gleason pattern 4/5 | 7 | 11.7: 11.1 | ||||
| Stolzenburg 2010 | Y | cT1/2a and PSA < 10 and Gleason score ≤ 3 + 4 | 9 | 89: 81 | 6.2: 5.6 | 31.8: 26.3 | 9.0: 9.5 | |
Intra-RP intrafascial radical prostatectomy, Inter-RP interfascial radical prostatectomy, SSOS Selection Score of Oncologic Safety, VIP Vattikuti Institute Prostatectomy, Y yes, N no.